Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
- PMID: 17302204
- PMCID: PMC2908852
- DOI: 10.3341/kjo.2006.20.4.205
Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
Abstract
Purpose: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.
Methods: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured.
Results: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection.
Conclusions: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.
Figures




Similar articles
-
Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.Ophthalmology. 2005 Sep;112(9):1557-63. doi: 10.1016/j.ophtha.2005.03.023. Ophthalmology. 2005. PMID: 16019075 Clinical Trial.
-
Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema.Clin Exp Ophthalmol. 2007 Nov;35(8):713-8. doi: 10.1111/j.1442-9071.2007.01578.x. Clin Exp Ophthalmol. 2007. PMID: 17997773
-
Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.J Diabetes Complications. 2006 Jul-Aug;20(4):246-51. doi: 10.1016/j.jdiacomp.2005.06.015. J Diabetes Complications. 2006. PMID: 16798476
-
Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.Acta Ophthalmol Scand. 2005 Dec;83(6):645-63. doi: 10.1111/j.1600-0420.2005.00592.x. Acta Ophthalmol Scand. 2005. PMID: 16396641 Review.
-
Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis.Curr Eye Res. 2012 Dec;37(12):1136-47. doi: 10.3109/02713683.2012.705412. Epub 2012 Jul 13. Curr Eye Res. 2012. PMID: 22793880
Cited by
-
Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.J Med Case Rep. 2021 Oct 22;15(1):518. doi: 10.1186/s13256-021-03129-1. J Med Case Rep. 2021. PMID: 34674724 Free PMC article.
-
Intravitreal steroids for the treatment of retinal diseases.ScientificWorldJournal. 2014 Jan 8;2014:989501. doi: 10.1155/2014/989501. eCollection 2014. ScientificWorldJournal. 2014. PMID: 24526927 Free PMC article. Review.
-
Scleral abscess following posterior subtenon triamcinolone acetonide injection for diabetic macular edema.Saudi J Ophthalmol. 2016 Apr-Jun;30(2):130-2. doi: 10.1016/j.sjopt.2015.12.007. Epub 2016 Jan 2. Saudi J Ophthalmol. 2016. PMID: 27330392 Free PMC article.
-
Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy.J Clin Med. 2021 Oct 12;10(20):4666. doi: 10.3390/jcm10204666. J Clin Med. 2021. PMID: 34682788 Free PMC article. Review.
-
Comparison of intravitreal preservative-free triamcinolone versus posterior sub-tenon triamcinolone acetonide injection for bevacizumab-resistant diabetic macular edema.BMC Ophthalmol. 2024 Jan 19;24(1):25. doi: 10.1186/s12886-024-03291-2. BMC Ophthalmol. 2024. PMID: 38243166 Free PMC article.
References
-
- Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–1806. - PubMed
-
- Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987;94:761–774. - PubMed
-
- Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse macular oedema: long-term visual results. Ophthalmology. 1991;98:1594–1602. - PubMed
-
- Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no.19. Arch Ophthalmol. 1995;113:1144–1155. - PubMed
-
- Martidis A, Duker JS, Greenberg PB, et al. Intravitreal Triamcinolone for Refractory Diabetic Macular Edema. Ophthalmology. 2002;109:920–927. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical